Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase II, Open Label, Randomized, Parallel Arm Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy Gemcitabine/Nab-paclitaxel, and Gemcitabine/Nab-paclitaxel Alone in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Commercial Sponsor
Novartis Pharmaceuticals
Summary
This is a randomised, open label trial with a safety run-in, two experimental arms, and one active comparator arm.
The safety run-in involes a combination of NIS793 + spartalizumab + gemcitabine + nab-paclitaxel.
Participants in Experimental Arm 1 will receive a combination of NIS793 + spartalizumab + gemcitabine + nab-paclitaxel.
Participants in Experimental Arm 2 will receive a combination of NIS793 + gemcitabine + nab-paclitaxel.
Participants in the Active Comparator arm will receive gemcitabine + nab-paclitaxel.